Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(16):6931-6954. doi:10.7150/thno.77949 This issue Cite

Review

Artificial intelligence in pancreatic cancer

Bowen Huang1,2*, Haoran Huang1,2*, Shuting Zhang1,2, Dingyue Zhang1,2, Qingya Shi2, Jianzhou Liu1, Junchao Guo1✉

1. Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.
2. School of Medicine, Tsinghua University, Beijing, 100084, China.
*These authors contributed equally to this work.

✉ Corresponding author: Junchao Guo, Tel.: +86-010-69152600; Fax: +86-010-69152601; E-mail: guojccn.

Citation:
Huang B, Huang H, Zhang S, Zhang D, Shi Q, Liu J, Guo J. Artificial intelligence in pancreatic cancer. Theranostics 2022; 12(16):6931-6954. doi:10.7150/thno.77949. https://www.thno.org/v12p6931.htm
Other styles

File import instruction

Abstract

Graphic abstract

Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%. The pancreatic cancer patients diagnosed with early screening have a median overall survival of nearly ten years, compared with 1.5 years for those not diagnosed with early screening. Therefore, early diagnosis and early treatment of pancreatic cancer are particularly critical. However, as a rare disease, the general screening cost of pancreatic cancer is high, the accuracy of existing tumor markers is not enough, and the efficacy of treatment methods is not exact. In terms of early diagnosis, artificial intelligence technology can quickly locate high-risk groups through medical images, pathological examination, biomarkers, and other aspects, then screening pancreatic cancer lesions early. At the same time, the artificial intelligence algorithm can also be used to predict the survival time, recurrence risk, metastasis, and therapy response which could affect the prognosis. In addition, artificial intelligence is widely used in pancreatic cancer health records, estimating medical imaging parameters, developing computer-aided diagnosis systems, etc. Advances in AI applications for pancreatic cancer will require a concerted effort among clinicians, basic scientists, statisticians, and engineers. Although it has some limitations, it will play an essential role in overcoming pancreatic cancer in the foreseeable future due to its mighty computing power.

Keywords: Artificial intelligence, machine learning, pancreatic cancer, early detection, prognosis prediction

Citation styles

APA
Huang, B., Huang, H., Zhang, S., Zhang, D., Shi, Q., Liu, J., Guo, J. (2022). Artificial intelligence in pancreatic cancer. Theranostics, 12(16), 6931-6954. https://doi.org/10.7150/thno.77949.

ACS
Huang, B.; Huang, H.; Zhang, S.; Zhang, D.; Shi, Q.; Liu, J.; Guo, J. Artificial intelligence in pancreatic cancer. Theranostics 2022, 12 (16), 6931-6954. DOI: 10.7150/thno.77949.

NLM
Huang B, Huang H, Zhang S, Zhang D, Shi Q, Liu J, Guo J. Artificial intelligence in pancreatic cancer. Theranostics 2022; 12(16):6931-6954. doi:10.7150/thno.77949. https://www.thno.org/v12p6931.htm

CSE
Huang B, Huang H, Zhang S, Zhang D, Shi Q, Liu J, Guo J. 2022. Artificial intelligence in pancreatic cancer. Theranostics. 12(16):6931-6954.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use